Skip to main content

Advertisement

SpringerLink
Log in

Nestin Expression Is Associated with Poor Clinicopathological Features and Prognosis in Glioma Patients: an Association Study and Meta-analysis

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Nestin has been identified as a molecular marker of neural progenitor cells and putative glioma stem cells (GSCs). Various studies examining the relationship between nestin expression with the clinical outcome in glioma patients have yielded inconclusive results. Thus, we conducted a systematic review to evaluate the association of nestin with prognosis and clinicopathological features of glioma patients. The electronic searches were performed through the database of PubMed, MEDLINE, Embase, and CNKI. In total, this meta-analysis included 14 studies covering 897 nestin + cases and 704 controls. The correlation between nestin expression and clinicopathological or prognostic parameters was evaluated by Stata 11.0 software. Our results showed that nestin protein abundance was significantly correlated with the histological grade [odds ratio (OR) = 4.36, 95 % confidence interval (CI) = 2.14–8.88, P = 0.003] of glioma. With respect to prognosis, nestin expression was positively correlated with overall survival (OS) [hazard ratio (HR) = 1.98, 95 % CI = 1.30–3.02, P = 0.000] and progression-free survival (PFS) (HR = 1.90, 95 % CI = 1.18–3.07, P = 0.040). The further stratified analysis not only defined the predictive function of nestin in different ages but also revealed that different antibodies did not alter the positive outcomes and higher standard cutoff values were more suitable for the accurate assay of nestin. Taken together, our results indicate that nestin may play an important role in the prediction of the clinicopathology and poor prognosis of glioma patients. This study should be taken into consideration in the development of new diagnostic and therapeutic programs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. doi:10.1007/s00401-007-0243-4

    Article  PubMed  PubMed Central  Google Scholar 

  2. Meyer MA (2008) Malignant gliomas in adults. N Engl J Med 359(17):1850. doi:10.1056/NEJMc086380, author reply 1850

    CAS  PubMed  Google Scholar 

  3. Sampetrean O, Saya H (2013) Characteristics of glioma stem cells. Brain Tumor Pathol 30(4):209–214. doi:10.1007/s10014-013-0141-5

    Article  CAS  PubMed  Google Scholar 

  4. Ishiwata T, Matsuda Y, Naito Z (2011) Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. World J Gastroenterol 17(4):409–418. doi:10.3748/wjg.v17.i4.409

    Article  PubMed  PubMed Central  Google Scholar 

  5. Dong J, Zhao Y, Huang Q, Fei X, Diao Y, Shen Y, Xiao H, Zhang T et al (2011) Glioma stem/progenitor cells contribute to neovascularization via transdifferentiation. Stem Cell Rev 7(1):141–152. doi:10.1007/s12015-010-9169-7

    Article  PubMed  Google Scholar 

  6. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA (2009) Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res 69(11):4708–4715. doi:10.1158/0008-5472.Can-08-4417

    Article  CAS  PubMed  Google Scholar 

  7. Teranishi N, Naito Z, Ishiwata T, Tanaka N, Furukawa K, Seya T, Shinji S, Tajiri T (2007) Identification of neovasculature using nestin in colorectal cancer. Int J Oncol 30(3):593–603

    CAS  PubMed  Google Scholar 

  8. Ehrmann J, Kolar Z, Mokry J (2005) Nestin as a diagnostic and prognostic marker: immunohistochemical analysis of its expression in different tumours. J Clin Pathol 58(2):222–223. doi:10.1136/jcp.2004.021238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Dahlrot RH (2014) The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dan Med J 61(10):B4944

    PubMed  Google Scholar 

  10. Strojnik T, Rosland GV, Sakariassen PO, Kavalar R, Lah T (2007) Neural stem cell markers, nestin and Musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 68(2):133–143. doi:10.1016/j.surneu.2006.10.050, discussion 143–134

    Article  PubMed  Google Scholar 

  11. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J (2008) Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 27:85. doi:10.1186/1756-9966-27-85

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kim KJ, Lee KH, Kim HS, Moon KS, Jung TY, Jung S, Lee MC (2011) The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology 31(5):494–502. doi:10.1111/j.1440-1789.2010.01194.x

    Article  PubMed  Google Scholar 

  13. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. doi:10.1186/1745-6215-8-16

    Article  PubMed  PubMed Central  Google Scholar 

  14. Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54(10):1046–1055

    Article  CAS  PubMed  Google Scholar 

  15. Xu L, Dong J, Lan Q (2009) Expression of stem cell markers: CD133 and nestin in gliomas of different malignancy and the correlation with patients’ prognosis. Chin J Neurooncol 7(3):175–179

    CAS  Google Scholar 

  16. Dahlrot RH, Hansen S, Jensen SS, Schroder HD, Hjelmborg J, Kristensen BW (2014) Clinical value of CD133 and nestin in patients with glioma: a population-based study. Int J Clin Exp Pathol 7(7):3739–3751

    PubMed  PubMed Central  Google Scholar 

  17. Dahlstrand J, Collins VP, Lendahl U (1992) Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 52(19):5334–5341

    CAS  PubMed  Google Scholar 

  18. Maderna E, Salmaggi A, Calatozzolo C, Limido L, Pollo B (2007) Nestin, PDGFRbeta, CXCL12 and VEGF in glioma patients: different profiles of (pro-angiogenic) molecule expression are related with tumor grade and may provide prognostic information. Cancer Biol Ther 6(7):1018–1024

    Article  CAS  PubMed  Google Scholar 

  19. Chinnaiyan P, Wang M, Rojiani AM, Tofilon PJ, Chakravarti A, Ang KK, Zhang HZ, Hammond E et al (2008) The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group. Radiat Oncol 3:32. doi:10.1186/1748-717X-3-32

    Article  PubMed  PubMed Central  Google Scholar 

  20. Ma YH, Mentlein R, Knerlich F, Kruse ML, Mehdorn HM, Held-Feindt J (2008) Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol 86(1):31–45. doi:10.1007/s11060-007-9439-7

    Article  PubMed  Google Scholar 

  21. Kanamori M, Kumabe T, Sonoda Y, Nishino Y, Watanabe M, Tominaga T (2009) Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors. J Neuro-Oncol 93(2):219–228. doi:10.1007/s11060-008-9762-7

    Article  Google Scholar 

  22. Wan F, Herold-Mende C, Campos B, Centner FS, Dictus C, Becker N, Devens F, Mogler C et al (2011) Association of stem cell-related markers and survival in astrocytic gliomas. Biomarkers 16(2):136–143. doi:10.3109/1354750X.2010.536256

    Article  CAS  PubMed  Google Scholar 

  23. Arai H, Ikota H, Sugawara K, Nobusawa S, Hirato J, Nakazato Y (2012) Nestin expression in brain tumors: its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas. Brain Tumor Pathol 29(3):160–167. doi:10.1007/s10014-012-0081-5

    Article  CAS  PubMed  Google Scholar 

  24. Milde T, Hielscher T, Witt H, Kool M, Mack SC, Deubzer HE, Oehme I, Lodrini M et al (2012) Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol 22(6):848–860. doi:10.1111/j.1750-3639.2012.00600.x

    Article  PubMed  Google Scholar 

  25. Ballester LY, Wang Z, Shandilya S, Miettinen M, Burger PC, Eberhart CG, Rodriguez FJ, Raabe E et al (2013) Morphologic characteristics and immunohistochemical profile of diffuse intrinsic Pontine gliomas. Am J Surg Pathol 37(9):1357–1364. doi:10.1097/PAS.0b013e318294e817

    Article  PubMed  PubMed Central  Google Scholar 

  26. Korkolopoulou P, Levidou G, El-Habr EA, Adamopoulos C, Fragkou P, Boviatsis E, Themistocleous MS, Petraki K et al (2013) Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival. Br J Cancer 108(10):2142–2152. doi:10.1038/bjc.2013.176

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hatanpaa KJ, Hu TS, Vemireddy V, Foong C, Raisanen JM, Oliver D, Hiemenz MC, Burns DK et al (2014) High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas. J Neuro-Oncol 117(1):183–189. doi:10.1007/s11060-014-1376-7

    Article  CAS  Google Scholar 

  28. Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463

    Article  CAS  PubMed  Google Scholar 

  29. Qureshi IA, Mehler MF (2011) Epigenetics, nervous system tumors, and cancer stem cells. Cancers 3(3):3525–3556. doi:10.3390/cancers3033525

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kasper S (2008) Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev 4(3):193–201. doi:10.1007/s12015-008-9033-1

    Article  CAS  PubMed  Google Scholar 

  31. Bentivegna A, Conconi D, Panzeri E, Sala E, Bovo G, Vigano P, Brunelli S, Bossi M et al (2010) Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples. Cancer Sci 101(2):416–424. doi:10.1111/j.1349-7006.2009.01414.x

    Article  CAS  PubMed  Google Scholar 

  32. Okuno K, Ohta S, Kato H, Taga T, Sugita K, Takeuchi Y (2010) Expression of neural stem cell markers in malignant rhabdoid tumor cell lines. Oncol Rep 23(2):485–492

    CAS  PubMed  Google Scholar 

  33. Neradil J, Veselska R (2015) Nestin as a marker of cancer stem cells. Cancer Sci 106(7):803–811. doi:10.1111/cas.12691

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Sahlgren CM, Pallari HM, He T, Chou YH, Goldman RD, Eriksson JE (2006) A nestin scaffold links Cdk5/p35 signaling to oxidant-induced cell death. EMBO J 25(20):4808–4819. doi:10.1038/sj.emboj.7601366

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Han M, Guo L, Zhang Y, Huang B, Chen A, Chen W, Liu X, Sun S et al (2015) Clinicopathological and prognostic significance of CD133 in glioma patients: a meta-analysis. Mol Neurobiol. doi:10.1007/s12035-014-9018-9

    PubMed Central  Google Scholar 

  36. Liu Y, Lv DL, Duan JJ, Xu SL, Zhang JF, Yang XJ, Zhang X, Cui YH et al (2014) ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis. BMC Cancer 14:444. doi:10.1186/1471-2407-14-444

    Article  PubMed  PubMed Central  Google Scholar 

  37. Wu B, Sun CX, Feng F, Ge MH, Xia L (2015) Do relevant markers of cancer stem cells CD133 and nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis. J Exp Clin Cancer Res 34:44. doi:10.1186/s13046-015-0163-4, ARTN

    Article  PubMed  PubMed Central  Google Scholar 

  38. Simon R, Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69(6):979–985

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Oncology Center, The 105 Hospital of The People’s Liberation Army, 424 Changjiang West Road, Hefei, Anhui, China

    Donglai Lv, Lin Lu, Zongtao Hu, Zhenle Fei, Meiqin Liu & Lei Wei

  2. Pathology Department, The 105 Hospital of The People’s Liberation Army, 424 Changjiang West Road, Hefei, Anhui, China

    Jun Xu

  3. Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China

    Donglai Lv

Authors
  1. Donglai Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lin Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zongtao Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhenle Fei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meiqin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lei Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jun Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donglai Lv.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lv, D., Lu, L., Hu, Z. et al. Nestin Expression Is Associated with Poor Clinicopathological Features and Prognosis in Glioma Patients: an Association Study and Meta-analysis. Mol Neurobiol 54, 727–735 (2017). https://doi.org/10.1007/s12035-016-9689-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-016-9689-5

Keywords

Search

Navigation